1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. All News
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:35 2022-07-05 am EDT
54.90 EUR   +3.47%
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies - Form 6-K
PU
06/23GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
06/22TRANSCRIPT : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about GALAPAGOS NV
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
06/22TRANSCRIPT : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call
CI
06/22Pharmaceutical Group Galapagos Buys Cell Therapy Developers CellPoint, AboundBio For $2..
MT
06/21Galapagos Expands Cell Therapy Capabilities Through Two Acquisitions
MT
06/21Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
GL
06/21Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
GL
06/21Galapagos NV acquired CellPoint B.V. from ND Capital and others for approximately €..
CI
06/21Galapagos NV acquired Abound Bio, Inc. for $14 million.
CI
06/20Galapagos increases share capital through subscription right exercises
GL
06/20Galapagos increases share capital through subscription right exercises
AQ
06/20Galapagos NV announced that it expects to receive €1.459507 million in funding
CI
06/02GALAPAGOS : receives transparency notification from FMR LLC - Form 6-K
PU
06/01Galapagos receives transparency notification from FMR LLC
GL
06/01Galapagos receives transparency notification from FMR LLC
AQ
05/31GALAPAGOS : to showcase commitment to rheumatoid arthritis care at the upcoming European L..
PU
05/25Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European ..
GL
05/24Galapagos In-Licenses Drug Targets for Inflammatory Bowel Disease From Scipher
MT
05/20Intervest Offices & Warehouses Extends Lease Deals For Office Portfolio In Belgium
MT
05/09RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating
MT
05/06Galapagos creates new subscription right plans
GL
05/06Galapagos creates new subscription right plans
AQ
05/06TRANSCRIPT : Galapagos NV, Q1 2022 Earnings Call, May 06, 2022
CI
05/05Galapagos demonstrates regulatory and commercial progress in Q1 2022
GL
05/05Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27GALAPAGOS : announces appointment of Dr. Paul Stoffels as Chairman of the board - Form 6-K
PU
04/26Galapagos Names CEO As Chairman Under New Governance Structure
MT
04/26Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
GL
04/26Galapagos NV Announces Executive Appointments
CI
04/12E-therapeutics Achieves Key Milestones Under Collaboration with Galapagos
MT
04/12E-therapeutics plc Announces A Key Milestone in Its Collaboration with Galapagos
CI
04/11SUBJECT : Galapagos AGM/EGM 2022 April 11th, 2022 - Form 6-K
PU
04/11GALAPAGOS : Chairman letter to shareholders
PU
04/01GALAPAGOS : Glpg egm & agm 2022
PU
03/28Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION ..
CI
03/28Galapagos' Jyseleca Gets Japanese Nod For Ulcerative Colitis Treatment
MT
03/28Jyseleca® approved in Japan for ulcerative colitis
AQ
03/25GALAPAGOS : — Proposal of one-tier board structure & appointment of three new directo..
PU
03/24GALAPAGOS : Statutory auditor's report on the non-consolidated financial statements per 31..
PU
03/24CORRECTION : Galapagos publishes 2021 annual report and announces extraordinary and annual..
GL
03/24Galapagos publishes 2021 annual report and announces extraordinary and annual sharehold..
AQ
03/24GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
03/20GALAPAGOS NV(ENXTAM : GLPG) dropped from FTSE All-World Index
CI
03/18Galapagos increases share capital through subscription right exercises
AQ
02/28RBC Cuts Price Target on Galapagos to $60 From $63, Maintains Sector Perform Rating
MT
02/25TRANSCRIPT : Galapagos NV, 2021 Earnings Call, Feb 25, 2022
CI
02/24GALAPAGOS : 2021 results set stage for future growth - Form 6-K
PU
02/24Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/24Galapagos 2021 results set stage for future growth
GL
02/07GALAPAGOS : receives transparency notification from EcoR1 Capital - Form 6-K
PU
02/07GALAPAGOS : provides further insights into the treatment of ulcerative colitis at the Euro..
PU
02/03Galapagos receives transparency notification from EcoR1 Capital
AQ
02/02Galapagos provides further insights into the treatment of ulcerative colitis at the Eur..
AQ
02/02Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the Eur..
CI
01/28Bryan Garnier Double Upgrades Galapagos NV to Buy From Sell, Lowers PT to 65 Euros From..
MT
01/27Health Care Outperform Amid Fading Thursday Markets
MT
01/27Top Midday Gainers
MT
01/27Health Care Stocks Still Outperforming Amid Fading Thursday Markets
MT
01/27SECTOR UPDATE : Health Care
MT
01/27Galapagos Names Former Johnson & Johnson Executive Paul Stoffels CEO; Shares Soar
MT
01/27GALAPAGOS : appoints Paul Stoffels as Chief Executive Officer - Form 6-K
PU
01/26Galapagos Appoints Former Johnson & Johnson Exec to Succeed Retiring CEO
MT
01/26Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO
RE
01/26GALAPAGOS : creates new subscription right plan - Form 6-K
PU
01/26Galapagos creates new subscription right plan
AQ
01/26Galapagos appoints Paul Stoffels as Chief Executive Officer
AQ
01/26Galapagos NV Appoints Paul Stoffels as Chief Executive Officer
CI
01/19GALAPAGOS : JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WIT..
PU
01/18Galapagos Wins Expanded UK Nod for Inflammatory Bowel Disease Drug Jyseleca
MT
01/18Galapagos Gets UK Approval for Jyseleca to Treat Ulcerative Colitis
MT
01/18Jyseleca®▼ (filgotinib) licensed for the treatment of adult patients with moderat..
AQ
01/18Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Ag..
CI
01/14Galapagos Supervisory Board Creates 30,000 Subscription Rights Plan
MT
01/13GALAPAGOS : creates new subscription right plan - Form 6-K
PU
01/13Galapagos creates new subscription right plan
AQ
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on GALAPAGOS NV